Telix Pharmaceuticals guides FY 2026 revenue $950M–$970M and R&D $230M–$270M
Telix Pharmaceuticals guides FY 2026 revenue to $950M–$970M and expects total income above $1B, while reaffirming R&D expenditure of $230M–$270M, supported by other income from Regeneron.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.